Carmen Bozic

3.2k total citations · 2 hit papers
37 papers, 2.1k citations indexed

About

Carmen Bozic is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Carmen Bozic has authored 37 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Carmen Bozic's work include Polyomavirus and related diseases (13 papers), Full-Duplex Wireless Communications (7 papers) and Multiple Sclerosis Research Studies (5 papers). Carmen Bozic is often cited by papers focused on Polyomavirus and related diseases (13 papers), Full-Duplex Wireless Communications (7 papers) and Multiple Sclerosis Research Studies (5 papers). Carmen Bozic collaborates with scholars based in United States, Switzerland and Germany. Carmen Bozic's co-authors include Sandra Richman, Gary Bloomgren, Tatiana Plavina, Meena Subramanyam, Alfred Sandrock, James Scanlon, Sophia Lee, Christophe Hotermans, Susan Goelz and Gary K. Grunwald and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Neurology.

In The Last Decade

Carmen Bozic

35 papers receiving 2.0k citations

Hit Papers

Risk of Natalizumab-Associated Progressive Multifocal Leu... 2012 2026 2016 2021 2012 2023 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carmen Bozic United States 13 934 819 423 400 279 37 2.1k
Claudia Pföhler Germany 26 1.3k 1.4× 366 0.4× 224 0.5× 283 0.7× 497 1.8× 143 2.8k
Jean Hou United States 21 1.0k 1.1× 387 0.5× 572 1.4× 115 0.3× 439 1.6× 52 2.3k
Luciano Lombardi Italy 22 695 0.7× 158 0.2× 144 0.3× 740 1.9× 400 1.4× 63 2.3k
Anna Fogdell‐Hahn Sweden 26 678 0.7× 1.1k 1.3× 68 0.2× 204 0.5× 707 2.5× 89 2.6k
Katherine Miszkiel United Kingdom 29 940 1.0× 3.0k 3.7× 122 0.3× 109 0.3× 665 2.4× 47 4.4k
Tatiana Plavina United States 22 1.4k 1.5× 1.4k 1.8× 504 1.2× 37 0.1× 480 1.7× 46 2.6k
Gary Bloomgren United States 12 1.1k 1.2× 930 1.1× 407 1.0× 44 0.1× 313 1.1× 17 2.1k
Elimelech Okon Israel 22 381 0.4× 303 0.4× 64 0.2× 245 0.6× 232 0.8× 72 1.7k
Esperanza Jordá Spain 19 590 0.6× 253 0.3× 110 0.3× 143 0.4× 158 0.6× 127 1.5k
Ralph J. Tuthill United States 29 1.3k 1.4× 441 0.5× 66 0.2× 353 0.9× 631 2.3× 84 2.7k

Countries citing papers authored by Carmen Bozic

Since Specialization
Citations

This map shows the geographic impact of Carmen Bozic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Bozic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Bozic more than expected).

Fields of papers citing papers by Carmen Bozic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Bozic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Bozic. The network helps show where Carmen Bozic may publish in the future.

Co-authorship network of co-authors of Carmen Bozic

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Bozic. A scholar is included among the top collaborators of Carmen Bozic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Bozic. Carmen Bozic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bertoch, Todd, Daneshvari R. Solanki, Matthew W. Swisher, et al.. (2025). Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 142(6). 1085–1099. 11 indexed citations
2.
Zemanick, Edith T., Bonnie W. Ramsey, Dorota Sands, et al.. (2025). Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. Journal of Cystic Fibrosis. 24(2). 246–254. 6 indexed citations
3.
Jones, J. W., Darin Correll, Sandra Lechner, et al.. (2023). Selective Inhibition of Na V 1.8 with VX-548 for Acute Pain. New England Journal of Medicine. 389(5). 393–405. 110 indexed citations breakdown →
4.
Dong‐Si, Tuan, Sarah Gheuens, Madé Wenten, et al.. (2015). Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. Journal of NeuroVirology. 21(6). 637–644. 75 indexed citations
5.
Cristiano, Lynda M., et al.. (2013). Evaluation of Pregnancy Outcomes from the TYSABRI® (Natalizumab) Pregnancy Exposure Registry (P02.127). Neurology. 80(7_supplement). 20 indexed citations
6.
Bozic, Carmen, et al.. (2013). Anti‐JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. European Journal of Neurology. 21(2). 299–304. 68 indexed citations
7.
Bloomgren, Gary, Sandra Richman, Christophe Hotermans, et al.. (2012). Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine. 366(20). 1870–1880. 878 indexed citations breakdown →
8.
Cristiano, Lynda M., et al.. (2012). Natalizumab Use in Patients With Crohnʼs Disease (CD) and Relapsing Multiple Sclerosis (MS): Updated Utilization and Safety Results. Inflammatory Bowel Diseases. 18. S67–S67. 2 indexed citations
9.
Bloomgren, Gary, Sandra Richman, Christophe Hotermans, et al.. (2012). Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Survey of Anesthesiology. 56(6). 329–330. 8 indexed citations
11.
Bozic, Carmen, Sandra Richman, Tatiana Plavina, et al.. (2011). Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1. Annals of Neurology. 70(5). 742–750. 102 indexed citations
12.
Hyde, Robert, Carmen Bozic, G Belcher, et al.. (2009). FP33-WE-04 Utilization and safety of natalizumab in patients with relapsing multiple sclerosis in the post-marketing setting. Journal of the Neurological Sciences. 285. S110–S110. 2 indexed citations
14.
Lynch, Anne M., et al.. (2008). Idiopathic Pulmonary Fibrosis: Physiologic Tests, Quantitative CT Indexes, and CT Visual Scores as Predictors of Mortality. Radiology. 246(3). 935–940. 252 indexed citations
15.
Goffe, Bernard S., Kim Papp, David Gratton, et al.. (2005). An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clinical Therapeutics. 27(12). 1912–1921. 44 indexed citations
16.
Sadeghi, Hossein, et al.. (1978). An attempt to separate xiphopagus twins sharing a common heart, liver, and duodenum. Journal of Pediatric Surgery. 13(2). 139–142. 11 indexed citations
17.
Genton, N, et al.. (1977). [Functional radiological findings in Hirschsprung's disease and in other cases of dyschezia].. PubMed. 19(1). 111–22. 1 indexed citations
18.
Brook, C. G. D., H Wagner, M. Zachmann, et al.. (1973). Familial Occurrence of Persistent Müllerian Structures in Otherwise Normal Males. BMJ. 1(5856). 771–773. 91 indexed citations
19.
Bozic, Carmen, et al.. (1972). Right-to-Left Shunting through a Patent Ductus arteriosus in a Newborn with Myocardial Infarction. Cardiology. 57(6). 348–357. 8 indexed citations
20.
Bozic, Carmen. (1969). [Lesions due to endotracheal intubation in newborn infants].. PubMed. 24(5). 458–62. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026